Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | NEK2 | P51955 | 1/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15815401 | 0.89 | CHEK1 (0.70) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL15815987 | 0.83 | CHEK1 (0.70) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL15815321 | 0.81 | CHEK1 (0.66) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL23297330 | 0.80 | MEN1 (0.60) | MEN1KMT2APOLBHDAC1SMN1; SMN2 | |
| SCHEMBL15815675 | 0.80 | CHEK1 (0.65) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL15815833 | 0.80 | CHEK1 (0.65) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL4124593 | 0.79 | PDE4A (0.69) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL15815706 | 0.76 | CHEK1 (0.80) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL14494630 | 0.75 | MET (0.58) | CHEK1NEK2LIMK1TYRO3CLK4 | |
| SCHEMBL15815347 | 0.73 | CHEK1 (0.74) | CHEK1NEK2LIMK1TYRO3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | claimed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | claimed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | CHEK1 259/4885NEK2 337/4885LIMK1 2511/4885 |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | CHEK1 259/4885NEK2 337/4885LIMK1 2511/4885 |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | CHEK1 259/4885NEK2 337/4885LIMK1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.